Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 4/20 | 0.73 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | HBB | P68871 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 5/20 | 0.66 |
| ▸ | GAPDH | P04406 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421824 | 1.00 | HSPA8 (0.73) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL1421820 | 1.00 | HSPA8 (0.73) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL2452214 | 0.96 | HSPA8 (0.68) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL30237271 | 0.90 | HSPA8 (0.60) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL6761939 | 0.90 | HSPA8 (0.72) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL6761931 | 0.90 | HSPA8 (0.72) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL17406892 | 0.88 | HSPA8 (0.56) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL18858928 | 0.86 | HSPA8 (0.80) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL15906323 | 0.86 | HSPA8 (0.80) | HSPA8HSPA5RXFP1LMNATP53 | |
| SCHEMBL1135195 | 0.86 | HSPA8 (0.80) | HSPA8HSPA5RXFP1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | HSPA8 1928/4885HSPA5 2092/4885RXFP1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.